WAYNE P. FRANCO, M.D.; ARTHUR W. BRACEY, M.D.; KENNETH L. FRANCO, M.D.; CHARLES A. HUFNAGEL, M.D.; DIETMAR H. GLOGAR, M.D.; ROBERT A. KLONER, M.D., PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Based on an Interdepartmental UCLA Conference, Golde and associates (1) have presented a superb review of the current status of in-vitro research into humoral growth factors. Yet little account is given to the potential clinical importance of growth factors in the future treatment of diseases that involve abnormal cell proliferation, as is the case in cancer or diseases related to atherosclerosis.
Recently in-vivo angiogenesis by growth factors was shown by Gospodarowicz and associates (2) using the avascular rabbit cornea as a model. Fibroblastic growth factor or epidermal growth factor incorporated into a slow-release form of Elwax 40
FRANCO WP, BRACEY AW, FRANCO KL, HUFNAGEL CA, GLOGAR DH, KLONER RA. Fibroblastic Growth Factor and Infarct Size. Ann Intern Med. ;93:637–638. doi: 10.7326/0003-4819-93-4-637
Download citation file:
Published: Ann Intern Med. 1980;93(4):637-638.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use